Clinical Trials Logo

Clinical Trial Summary

OBJECTIVES: I. Determine whether intermittent, long-term, subcutaneous administration of calcitonin increases phosphaturia, reduces hyperphosphatemia, and increases intact parathyroid hormone levels in patients with tumoral calcinosis.

II. Determine whether calcitonin reduces or prevents tumor recurrence. III. Determine whether hyperphosphatemia abolishes the normal circadian pattern of serum phosphorus.

IV. Determine how repetitive calcitonin administration alters the biochemical markers of bone metabolism in osteopenic patients with tumoral calcinosis.


Clinical Trial Description

PROTOCOL OUTLINE: Patients are treated with subcutaneous injections of salmon calcitonin every 3 weeks. Ondansetron premedication and intravenous hydration are also administered.

Patients are followed for disease progression and tumor recurrence. ;


Study Design

Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00004358
Study type Interventional
Source National Center for Research Resources (NCRR)
Contact
Status Completed
Phase Phase 2
Start date November 1992

See also
  Status Clinical Trial Phase
Completed NCT02062125 - Calcinosis in a Single-Center Scleroderma Population
Completed NCT02663895 - Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis Phase 2
Completed NCT00211939 - CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients Phase 4
Not yet recruiting NCT06155578 - Safety and Efficacy of Topical Sodium Metabisulfite for the Treatment of Calcinosis in Patients With Systemic Sclerosis Phase 1/Phase 2
Completed NCT01572844 - Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis Phase 2
Completed NCT02419040 - Treatment of Calcific Tendinitis of the Rotator Cuff N/A